PJPrathap Jayaram

Prathap Jayaram

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Prathap Jayaram has a total of 85 co-authors. Here are the top co-authors by number of shared publications:

  • Joanne Borg‐Stein

    Division of Sports and Musculoskeletal Rehabilitation, Associate Director, Harvard/Spaulding Sports Medicine Fellowship, Department of Physical Medicine and Rehabilitation Harvard Medical School Boston Massachusetts USA

    3 shared publications
  • Shiv J. Patel

    Joseph Barnhart Department of Orthopedic Surgery, Baylor College of Medicine, Houston, Texas

    3 shared publications
  • Bo Song

    H. Ben Taub Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, Texas

    2 shared publications
  • Christine Townsend

    Montefiore Med Ctr/Albert Einstein COM Yeshiva Univ Sports Medicine Fellowship New York New York USA

    2 shared publications
  • Erek Latzka

    Department of Orthopedics and Rehabilitation Tufts Medical Center Boston Massachusetts USA

    2 shared publications
  • John Cianca

    Human Performance Center Bellaire Texas USA

    2 shared publications

Latest Publications

  • SPOT: An Early Detection Tool for Predicting Pain Trajectories Following Intra‐Articular Injections

    by Brittany L. Nelson, Prathap Jayaram, Scott D. Boden, Kenneth Mautner, Michael B. Gottschalk, Gregory D. Myer, Hicham Drissi, Jed A. Diekfuss

    The purpose of this study was to identify 12‐month postinjection knee osteoarthritis (KOA) pain trajectories and develop an early prediction model using patient‐reported pain scores. Data were derived from a multi‐site, single‐blind randomized controlled trial of intra‐articular injections for KOA. The primary analysis focused on participants assigned to autologous bone marrow aspirate concentrate, umbilical cord tissue‐derived mesenchymal stromal cells, or stromal vascular fraction. After data‐quality screening, the primary trajectory cohort included 317 participants and the prediction cohort included 295 participants with Screening and Month‐3 KOOS‐12 Pain scores. Latent class mixed‐effects modeling identified a two‐class solution selected for clinical interpretability: 66.6% of patients followed an Improved Pain trajectory and 33.4% followed a Persistent Pain trajectory. Although a three‐class model had slightly lower BIC, the additional class included only 2.5% of participants and was not retained for the clinical prediction tool. A logistic regression model using KOOS‐12 Pain at Screening and 3‐month change predicted trajectory membership with AUC = 0.785 in training and AUC = 0.792 in the held‐out test set. A training‐selected threshold of 0.656 yielded held‐out test sensitivity = 0.790, specificity = 0.692, PPV = 0.860, NPV = 0.581, and accuracy = 0.761. The resultant model was implemented as the Symptom Prediction for Outcomes of Treatment (SPOT) web calculator. Clinical Significance: The SPOT web calculator only requires KOOS‐12 Pain data from Screening and Month 3 to classify patients as likely to follow an Improved Pain vs. Persistent Pain trajectory after orthobiologic KOA treatment. Trial Registration: ClinicalTrials.gov identifier: NCT03818737

  • AAPM &R guidance statement on platelet rich plasma for knee osteoarthritis

    by Joanne Borg‐Stein, Prathap Jayaram, Berdale S. Colorado, Arthur Jason de Luigi, Michael Khadavi, Erek Latzka, William J. Naber, Shounuck Patel, Walter I. Sussman, Xiaoning Yuan, et al.

    Background: The current nonoperative standard‐of‐care therapies for knee osteoarthritis (OA) include weight reduction, physical therapy, analgesics, optimization of biomechanics, and intra‐articular injection of corticosteroids. Platelet rich plasma (PRP) is an orthobiologic intervention that is increasingly used in patients with knee OA, primarily due to its many key mediators that can potentially reduce joint inflammation thereby improving pain and enhancing overall joint function. The American Academy of Physical Medicine and Rehabilitation (AAPM&R) convened a technical expert panel (TEP) to summarize and assess the evidence for use of PRP in patients with knee OA and synthesize current knowledge into a summary document that can serve as a resource for clinicians. We address many of the questions and decision points that practitioners need to consider for responsible use of PRP in knee OA. Objective: To develop consensus‐based practice recommendations to identify and address gaps in PRP applications in patients with knee OA. Methods: The AAPM&R orthobiologic TEP initiated development of this consensus guidance statement in March 2023. The TEP was responsible for formulating search terms and research questions and synthesizing evidence obtained from a structured literature review that was initially completed in April 2023 and subsequently updated to reflect studies published between May 2023 and June 2025. The recommended actions and best practices in this guidance reflect consensus being achieved by the expert physiatrists and supported by best available evidence, where available. These actions and practices were conceptualized in response to common questions this expert panel frequently encounter in the use and administration of PRP. The TEP was asked to consider the strengths and limitations of available evidence and augment with expert opinion focused on closing knowledge gaps guiding the delivery of PRP in patients with knee OA. Results: As a result of the structured literature review and use of a modified Delphi process to achieve consensus on clinical guidance for PRP use in patients with knee OA, the AAPM&R TEP on use of PRP in knee OA arrived at five evidence‐based clinical recommendations for PRP management and 11 consensus‐based best practices supported by expert opinion and limited evidence. Conclusion: This consensus guidance addresses common questions about the use of PRP in patients with knee OA and provides actionable recommendations and best practices based on expert opinion supported by best available evidence. Despite their growing availability as point‐of‐care interventions, orthobiologic therapies remain an evolving area of practice. Robust, dose‐dependent randomized controlled trials are needed to more clearly establish the clinical effects of PRP on patient outcomes. Clinical judgment should be exercised and management options tailored to individual patient needs, preferences, and risk profiles.


  • Open Access

    Safety and Efficacy of Autologous Bone-Marrow-Derived Mesenchymal Stem Cells for Treating Partial Rotator Cuff Tears: Observational Study with 4-Year Follow-Up

    by Nicholas Hooper, Ahmad Alhusen, Hinnah Siddiqui, John Pitts, Prathap Jayaram, Chirstopher J. Williams

    Background/Objectives: Rotator cuff tears (RCTs) are a leading cause of shoulder pain and disability. Management typically involves conservative measures, such as physical therapy and anti-inflammatory medications, or surgery for full-thickness or refractory tears. Regenerative medicine therapies, including platelet-rich plasma (PRP), platelet lysate (PL), and mesenchymal stem cells (MSCs), show promise as alternative treatment strategies, although long-term outcomes remain under investigation. Methods: This cohort included 30 patients with partial rotator cuff tears and were treated with culture-expanded MSC injections. There was no control group. Inclusion criteria included an imaging-confirmed diagnosis of partial-thickness rotator cuff tears. Outcomes were assessed at multiple time points up to 6 years. Pain and function were assessed using the Disabilities of the Arm, Shoulder, and Hand (DASH), a Numeric Rating Scale (NRS), and the modified Single Assessment Numeric Evaluation (SANE). Results: Thirty patients (37 shoulders) were included in the analysis. Significant improvements in the NRS and DASH scores were observed at 3, 6, 12, 18, and 24 months (p < 0.01). Twenty-four months post-treatment, the mean NRS and DASH decreased by 2.25 and 15.93 points, respectively, and SANE improved by 60%. At six years, among seven respondents, the mean SANE improvement was 75.54%. During this study, no significant adverse events were reported. Conclusions: This study provides the longest known follow-up of MSC therapy for partial-thickness RCTs, finding sustained pain and functional improvements. The findings support further research into MSC-based and combination regenerative therapies as a viable alternative treatment option for partial-thickness rotator cuff tears.

  • Ethical and Regulatory Considerations Related to Regenerative Medicine

    by Prathap Jayaram, Richard M. Danilkowicz, Xiaoning Yuan

    The possibility of modifying disease through regenerative medicine applications, particularly stem cell therapies, raises ethical and regulatory challenges in orthopedics. This review article provides historical context of stem cell research, ethical issues such as informed consent, therapeutic misconception, and equitable access, emphasizing the responsibilities of providers offering investigational treatments. It also examines the evolving role of the U.S. Food and Drug Administration (FDA) in regulating regenerative therapies through frameworks like the Regenerative Medicine Advanced Therapy (RMAT) designation, and more point-of-care enforcement discretion policies for therapies such as autologous micro-fragmented adipose tissue and bone marrow aspirate concentrate. The authors underscore the importance of innovative therapies to address unmet needs in musculoskeletal healthcare while acknowledging the need for more rigorous basic and clinical research. They call for a continuous refinement of regulatory and ethical standards as regenerative medicine advances.


  • Open Access

    Exploring Metabolic Mechanisms in Calcific Tendinopathy and Shoulder Arthrofibrosis: Insights and Therapeutic Implications

    by Shahenvaz Alam, Marisa Shauna Sargeant, Ronak Patel, Prathap Jayaram

    Rotator cuff calcific tendinopathy and arthrofibrosis of the shoulder (adhesive capsulitis) are debilitating musculoskeletal disorders that significantly impact joint function and impair quality of life. Despite its high prevalence and common clinical presentation, the metabolic mechanisms underlying these conditions characterized by pain, and reduced mobility, remain poorly understood. This review aims to elucidate the role of metabolic processes implicated in the pathogenesis of calcific tendinopathy and shoulder arthrofibrosis. We will be focusing on the mechanistic role of how these processes contribute to disease progression and can direct potential therapeutic targets. Calcific tendinopathy is marked by aberrant calcium deposition within tendons, influenced by disrupted calcium and phosphate homeostasis, and altered cellular responses. Key molecular pathways, including bone morphogenetic proteins (BMPs), Wnt signaling, and transforming growth factor-beta (TGF-β), play crucial roles in the pathophysiology of calcification, calcium imbalance, and muscle fibrosis. In contrast, shoulder arthrofibrosis involves excessive collagen deposition and fibrosis within the shoulder joint capsule, driven by metabolic dysregulation and inflammation. The TGF-β signaling pathway and inflammatory cytokines, such as interleukin-6 (IL-6), are central to the fibrotic response. A comparative analysis reveals both shared and distinct metabolic pathways between these conditions, highlighting the interplay between inflammation, cellular metabolism, extracellular matrix remodeling, calcific deposition, and calcium migration to the glenohumeral joints, resulting in adhesive capsulitis, thereby providing insights into their pathophysiology. This review discusses current therapeutic approaches and their limitations, advocating for the development of targeted therapies that address specific metabolic dysregulations. Future therapeutic strategies focus on developing targeted interventions that address the underlying metabolic dysregulation, aiming to improve patient outcomes and advance clinical management. This review offers a comprehensive overview of the metabolic mechanisms involved in calcific tendinopathy and shoulder arthrofibrosis, providing a foundation for future research and therapeutic development.


  • Curriculum for training in orthobiologics

    by Michael Auriemma, Haylee Borgstrom, David Itskevich, Ryan Kruse, Erek Latzka, Josh Martin, Brittany Moore, Marc Gruner, Marko Bodor, John Cianca, et al.


  • Developing and integrating an orthobiologics curriculum

    by Walter I. Sussman, Michael Auriemma, Marko Bodor, John Cianca, Prathap Jayaram, Karen Knight, Christine Townsend, Joanne Borg‐Stein


  • Open Access

    Cell-Based Therapies for Rotator Cuff Injuries: An Updated Review of the Literature

    by Nicholas Hooper, Anuj Marathe, Nitin B. Jain, Prathap Jayaram

    This review focuses on non-surgical treatment options for rotator cuff injuries and highlights the potential of mesenchymal stem cells (MSCs) as a potential regenerative approach. MSCs, sourced from various tissues like bone marrow and adipose tissue, exhibit promising mechanisms in vitro, influencing tendon-related gene expression and microenvironment modulation. Animal studies support this, showcasing MSCs’ ability to reduce inflammation, improve tissue remodeling, and enhance repaired tendon strength. Human trials, while varied and limited, suggest that MSCs might lower retear rates and enhance post-repair outcomes, but randomized controlled trials yield mixed results, emphasizing the necessity for standardized investigations. Ultimately, while cell-based therapies demonstrate an excellent safety profile, more rigorous clinical trials are necessary to determine their efficacy in improving patient outcomes and achieving lasting structural changes in rotator cuff injuries.


  • Open Access

    Mesenchymal stem cells for subchondral bone marrow lesions: From bench to bedside

    by Rosa M. Pasculli, Charles D. Kenyon, William A. Berrigan, Kenneth Mautner, Kyle Hammond, Prathap Jayaram